WUH: 07480-Randomized trial of COBRA PzF Stenting To Reduce Duration of Triple Therapy (COBRA-REDUCE)
Brief description of study
The purpose of the study is to collect information about the safety and effectiveness of the COBRA PzF Coronary Stent System in the treatment of new lesions in original coronary arteries with a shortened duration of dual antiplatelet therapy. This device has received CE mark in the European Union (EU) and recently received FDA approval in the US and is commercially available for use in those markets.
Clinical Study Identifier: s18-01212
ClinicalTrials.gov Identifier: NCT02594501
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
